A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors
NANot yet recruitingINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
February 28, 2023
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2025
Conditions
Solid Tumor
Interventions
BIOLOGICAL
HER2-E-CART cells
E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
All Listed Sponsors
lead
su haichuan
OTHER
NCT05745454 - A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors | Biotech Hunter | Biotech Hunter